PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 21, Pages 5535
Publisher
MDPI AG
Online
2021-11-04
DOI
10.3390/cancers13215535
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
- (2021) Loretta J. Nastoupil et al. LEUKEMIA & LYMPHOMA
- Idelalisib immune-related toxicity is associated with improved treatment response
- (2021) Nina D. Wagner-Johnston et al. LEUKEMIA & LYMPHOMA
- PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches
- (2021) Matteo Caforio et al. Cancers
- Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
- (2020) Dirk L. Kienle et al. EXPERT OPINION ON PHARMACOTHERAPY
- Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial.
- (2020) Huaqing Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation
- (2020) Anne-Katrien Stark et al. JOURNAL OF IMMUNOLOGY
- Parsaclisib Is a Next-Generation PI3Kδ Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
- (2020) Niu Shin et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
- (2020) Kamira Maharaj et al. Blood Advances
- Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
- (2020) Tycel J. Phillips et al. Clinical Lymphoma Myeloma & Leukemia
- PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
- (2020) Catherine L. Tan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma
- (2020) Thomas D. Rodgers et al. LEUKEMIA & LYMPHOMA
- Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
- (2020) Andrea Visentin et al. OncoTargets and Therapy
- Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
- (2020) Sarah Nicol Lauder et al. Journal for ImmunoTherapy of Cancer
- PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax
- (2020) Neus Serrat et al. Blood Advances
- Immunomodulation by targeted anticancer agents
- (2020) Giulia Petroni et al. CANCER CELL
- Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
- (2020) Ashley Hanlon et al. Hematology-American Society of Hematology Education Program
- Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
- (2019) Giuseppe Curigliano et al. DRUG SAFETY
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy
- (2019) Anna C. Beielstein et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lymphomas and Their Microenvironment: A Multifaceted Relationship
- (2019) Thomas Menter et al. PATHOBIOLOGY
- SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL
- (2019) Lei Fan et al. BLOOD
- On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
- (2019) Franck Morschhauser et al. MOLECULAR CANCER THERAPEUTICS
- INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)
- (2019) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
- (2018) Tycel J. Phillips et al. BLOOD
- PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment
- (2018) Xiaoyan Liu et al. Future Oncology
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
- (2018) Silvia Martinelli et al. HAEMATOLOGICA
- Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
- (2018) Marie de Charette et al. HAEMATOLOGICA
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- (2018) Jake S. O’Donnell et al. SEMINARS IN CANCER BIOLOGY
- Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
- (2018) Silvia Martinelli et al. HAEMATOLOGICA
- Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
- (2018) Marie de Charette et al. HAEMATOLOGICA
- Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
- (2018) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study
- (2018) Susan O'Brien et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
- (2018) Antonio Cuneo et al. HEMATOLOGICAL ONCOLOGY
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530
- (2018) Silvia L. Locatelli et al. CLINICAL CANCER RESEARCH
- PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
- (2018) Shuai Dong et al. JOURNAL OF CLINICAL INVESTIGATION
- PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
- (2018) Bola S. Hanna et al. LEUKEMIA
- PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
- (2017) Benjamin L. Lampson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- COPANLISIB IN COMBINATION WITH ANTI-PD-1 INDUCES REGRESSION IN ANIMAL TUMOR MODELS INSENSITIVE OR RESISTANT TO THE MONOTHERAPIES OF PI3K AND CHECKPOINT INHIBITORS
- (2017) N. Liu et al. HEMATOLOGICAL ONCOLOGY
- Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K δ
- (2017) Rodger A. Allen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
- (2017) Klemens Hoegenauer et al. ACS Medicinal Chemistry Letters
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
- (2016) Elisa ten Hacken et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
- (2016) Changchun Deng et al. BLOOD
- Idelalisib in the management of lymphoma
- (2016) C. Y. Cheah et al. BLOOD
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
- (2016) William J. Scott et al. ChemMedChem
- Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis
- (2016) Friedrich Horak et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The transcription factor BACH2 promotes tumor immunosuppression
- (2016) Rahul Roychoudhuri et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability
- (2016) Leena Patel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells
- (2016) M Pizzi et al. LEUKEMIA
- Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity
- (2016) Chong T. Luo et al. NATURE
- BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers
- (2016) Rahul Roychoudhuri et al. NATURE IMMUNOLOGY
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Hypoxia and metabolic adaptation of cancer cells
- (2016) K L Eales et al. Oncogenesis
- High Levels of Regulatory T Cells in Blood Are a Poor Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma
- (2015) Chen Chang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Idelalisib-associated Enterocolitis
- (2015) Christine Y. Louie et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Idelalisib-associated Colitis
- (2015) Anna-Sophie Weidner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- From mice to humans: developments in cancer immunoediting
- (2015) Michele W.L. Teng et al. JOURNAL OF CLINICAL INVESTIGATION
- Control of Regulatory T Cell Migration, Function, and Homeostasis
- (2015) Daniel J. Campbell JOURNAL OF IMMUNOLOGY
- Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease
- (2015) Kenneth Down et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment
- (2015) M. D. Sharma et al. Science Advances
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease
- (2014) Timothy D. Cushing et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism
- (2013) Lazaros C. Foukas et al. EMBO Molecular Medicine
- Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729
- (2013) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
- (2013) Ryan P. P. Shugg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
- (2012) C. Qian et al. CLINICAL CANCER RESEARCH
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- T regulatory cells in B-cell malignancy - tumour support or kiss of death?
- (2011) Camilla A. Lindqvist et al. IMMUNOLOGY
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction
- (2010) J. Rolf et al. JOURNAL OF IMMUNOLOGY
- Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
- (2008) S. Mittal et al. BLOOD
- Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures
- (2008) Marie-Caroline Dieu-Nosjean et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-mediated dormancy: an equilibrium with cancer
- (2008) Michele W. L. Teng et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search